Document is current
Any future updates will be listed below
-
Authors
Iida, Shinsuke https://orcid.org/0000-0002-4951-960X
Sunami, Kazutaka https://orcid.org/0000-0002-8229-7439
Ito, Shigeki https://orcid.org/0000-0002-3899-6603
Yuda, Junichiro https://orcid.org/0000-0002-4908-1636
Fujikawa, Ei
Takamoto, Mikihiro
Aida, Kensuke
Yamazaki, Hiroshi
Takahashi, Marimo
Ishida, Tadao https://orcid.org/0000-0003-3219-3292
-
Funding
Funding for this research was provided by:
Janssen Japan
- License Information
-
More Information
Article History
Received: 29 November 2024
Revised: 10 April 2025
Accepted: 10 April 2025
First Online: 9 May 2025
Declarations
:
: Shinsuke Iida: All support for the present manuscript received from Janssen. Grants received from Abbvie, Amgen, BMS, Daiichi Sankyo, GSK, Janssen, Novartis, Ono, Otsuka, Pfizer Sanofi, Shionogi, and Takeda and paid to the institution. Consulting fees received from Abbvie, Astrazeneca, BMS, GSK, Janssen, Novartis, Otsuka, Pfizer, and Sanofi. Payment or honoraria received from Astrazeneca, BMS, Janssen, Pfizer, Sanofi, and Takeda, paid to the author. Other financial or non-financial interests received from Chugai as subsidy. Kazutaka Sunami: Grants as research funding received from: Abbvie, Beigene, BMS, Chugai, GSK, Incyte, Janssen, Kyowa Kirin, Mitsubishi Tanabe, Novartis, Ono, Otsuka, Pfizer, and Sanofi. Honoraria received from BMS, Janssen, and Sanofi. Shigeki Ito: Grant or research funding received from Abbvie, BMS, GSK, Janssen, Pfizer, and Sanofi. Honoraria received from BMS, Janssen, Pfizer, Takeda and Sanofi. Junichiro Yuda: has received research funding from AbbVie, Amgen, BMS, Chugai, Daiichi Sankyo, Genmab, Incyte, Janssen, Novartis, Mitsubishi Tanabe, MSD, Sumitomo, and Takeda. Participated on a data safety monitoring board or advisory board for Janssen. Ei Fujikawa: Employee of Janssen Pharmaceutical K.K. Mikihiro Takamoto: Employee of Janssen Pharmaceutical K.K. Kensuke Aida: Employee of Janssen Pharmaceutical K.K. Hiroshi Yamazaki: Employee of Janssen Pharmaceutical K.K., own stocks or stock options in Kameya Shoji Co., Ltd. Marimo Takahashi: Employee of Janssen Pharmaceutical K.K. Owns stock or stock options in J&J innovative medicine. Tadao Ishida: Grants as Research funding received from Alexion pharma, BMS, GSK, Janssen, Pfizer, Prothena, Sanofi, and Takeda. Payment or honoraria received from BMS, CSL Behring, Janssen, Ono, Pfizer, Sanofi, and Takeda.
: The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonization guidelines for Good Clinical Practice. The study, protocol along with any amendments, was approved by the institutional review boards at each participating study site. All patients also provided written informed consent.
